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 INTRODUCTION
 Primary biliary cholangitis (formerly named primary biliary cir-
rhosis, PBC) is a chronic liver disease characterized by progressive 
immune-mediated destruction of the small-to-medium-sized 
bile ducts, resulting in chronic cholestasis, portal infl amma-
tion and, eventually, cirrhosis ( 1 ). It mainly aff ects middle-aged 
women, and frequently coexists with various autoimmune dis-
eases. Th e probability of PBC being associated with at least one 
autoimmune disorder is reportedly as high as 61.1% ( 2 ), and thy-
roid diseases (TD) are one of the most common associations with 
PBC. Crowe  et al. ( 3 ) reported positivity for thyroid antibodies 
in 25 of 95 patients with PBC (26%); and 13 of these patients 
had biochemical evidence of thyroid dysfunction, usually hypo-
thyroidism (32%). A positive correlation emerged with thyroid 
antibodies and sicca syndrome, but not with histological stage 
of PBC. Elta  et al. ( 4 ) studied thyroid metabolism in 58 patients 
with PBC and found a 22% prevalence of hypothyroidism.
 Th e prevalence of TD in PBC reportedly ranges between 7.24 
and 14.4% ( 2–5 ), the most oft en encountered thyroid dysfunction 
being Hashimoto’s thyroiditis. TDs are also commonly associated 
with primary sclerosing cholangitis ( 6 ), and autoimmune hepa-
titis ( 7,8 ). Th e frequency of TD in autoimmune liver diseases is 
substantially higher than in the general population. Since fatigue, 
lethargy, anorexia, and hypercholesterolemia are common features 
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of both hypothyroidism and PBC, patients with PBC should be 
screened for evidence of TD ( 5 ). In addition, little attention has 
been paid in the literature to the infl uence of TD on the natural 
history of PBC.
 Th e aim of the present study conducted at two European cent-
ers was to analyze the association between PBC and TD, and the 
impact of the latter on the natural history of PBC.
 METHODS
 All PBC patients were seen prospectively and included in a 
database (1975–2015). A detailed description of our recruit-
ment methods and diagnostic and follow-up criteria is available 
elsewhere ( 9 ). Th e present study concerns all consecutive PBC 
patients collected between 1975 and February 2015 who had a 
follow-up of at least 1 year. PBC was diagnosed on the basis of 
an antimitochondrial antibody (AMA) positivity higher than 
1:40, abnormal alkaline phosphatase levels (at least 1.5 times the 
norm), and/or a compatible liver histology. Th e AMA-negative 
variant was diagnosed in patients with abnormal alkaline phos-
phatase levels (at least 1.5 times the norm), an antinuclear anti-
body positivity of at least 1:40, and a liver histology compatible 
with PBC. In AMA-negative patients, biliary tree patency was 
assessed by ultrasound and nuclear magnetic resonance imaging 
with cholangiography. Histological staging was done according 
to Scheuer’s classifi cation ( 10 ).
 Th e diagnosis of Hashimoto’s thyroiditis was established from a 
combination of clinical features, the presence of serum antibodies 
against thyroid antigens (mainly thyroperoxidase and thyroglobu-
lin), and thyroid sonography ( 11 ). Graves’ disease was diagnosed 
in the presence of one or more of the following features in a thyro-
toxic patient: detectable thyroid antibodies in the serum; evidence 
of ophthalmopathy and/or dermopathy; and diff use and increased 
thyroid radio-iodine uptake ( 12 ). Multinodular goiter was diag-
nosed on the basis of a clinical assessment, including physical 
examination; ultrasound; fi ne-needle aspiration biopsy to exclude 
malignancy; and serum TSH assay to assess thyroid function ( 13 ).
 Patient follow-up and event assessment
 All patients were assessed at 4- to 6-monthly intervals at the 
outpatients clinic by the same dedicated staff , who recorded 
clinical signs and symptoms of liver disease and extrahepatic 
autoimmunity, and laboratory parameters including aspartate 
aminotransferase, alanine aminotransferase, gamma-glutamyl 
transferase, bilirubin, prothrombin time, alkaline phosphatase, 
serum albumin, IgG, IgA, IgM, total cholesterol, platelet and leu-
kocyte counts, and hemoglobin. Alpha-fetoprotein was assessed 
every 6 months in patients with features of advanced disease. 
Liver ultrasound was performed annually in patients in the pre-
cirrhotic stage, and every 6 months in those in histological stage 
IV. From 1987 onwards, all patients were treated with ursodeoxy-
cholic acid (UDCA) at a dose of 15 mg/kg/day. Only eight patients 
with systemic lupus erythematosus (SLE) or rheumatoid arthritis 
(RA) were treated with prednisolone or prednisone, tapered to a 
maintenance dose of 7.5 mg/day. Patients with hepatitis B or C 
infections were excluded for the purposes of this study. Fatigue 
was assessed in 339 subjects using the PBC-40 questionnaire, a 
fully validated, PBC-specifi c multidomain tool assessing quality 
of life ( 14 ); fatigue was scored on a 5-point scale (≤11=absent; 
12–23=mild; 24–34=moderate; 35–45=severe; >45=extreme).
 Th e mean follow-up was 126.9±91.7 months. Th e onset of major 
complications during the follow-up was classifi ed as follows: HCC 
was diagnosed by ultrasound (US), computed tomography (CT), 
or nuclear magnetic resonance imaging (NMRI), as appropriate; 
ascites was identifi ed clinically or by abdominal US; gastrointesti-
nal bleeding due to portal hypertension was confi rmed by endos-
copy in cases of esophageal or gastric varices, or hypertensive 
gastropathy; portal-systemic encephalopathy was established from 
clinical parameters according to the West Haven criteria ( 15 ). Th e 
study was approved by the local ethical committee and all partici-
pants gave their informed consent to the study.
 Statistical analyses
 Standard descriptive statistics were used to describe the sample’s 
characteristics. Th e chi-squared test was used to test for diff er-
ences in categorical variables between two independent groups, 
as appropriate, and Student’s  t -test was used for diff erences in 
continuous variables between two independent groups. A logistic 
regression analysis was run (with 95% confi dence intervals). Sur-
vival was analyzed with Kaplan–Meier curves (Breslow General-
ized Wilcoxon test), and Cox’s proportional model was applied in 
order to determine the presence of independent risk factors that 
may infl uence survival besides the presence of thyroid dysfunc-
tions. A  P value ≤0.05 was considered statistically signifi cant. Th e 
statistical analysis was conducted using SPSS soft ware (Chicago, 
IL, USA).
 RESULTS
 Table 1 shows the clinical characteristics of the study group. 
Th e two series of patients had similar demographic and clinical 
characteristics, except for smoking habit, with signifi cantly more 
smokers in Padova than in Barcelona (19.9 vs. 12.9%,  P <0.05). 
Th ere were more patients in histological stage III in Padova than 
in Barcelona (25.8 vs. 10.6%,  P <0.05). Th ere was no diff erence 
between the two cohorts regarding the prevalence of decompen-
sation events during the follow-up (ascites, variceal bleeding, 
spontaneous bacterial peritonitis, hepatic encephalopathy, and 
hepatocellular carcinoma).
 Among the 921 PBC patients, 150 (16.3%) had an associated 
TD, 117/921 (12.7%) with and 33/921 (3.6%) without an autoim-
mune etiology. No signifi cant diff erences emerged between the 
two cohorts regarding the presence of TD. Overall, 94 patients 
(10.2%) had Hashimoto’s thyroiditis, 15 (1.6%) had Graves’ dis-
ease, 22 (2.4%) had multinodular goiters, 7 (0.8%) had thyroid 
cancer, and 12 (1.3%) had other forms of TD. Autoimmune TD 
was identifi ed in 117 PBC patients (78% of the 150 patients with 
associated TD), with a similar prevalence in the two cohorts (78.6 
and 77.5% in Padova and Barcelona, respectively).  Table 2 shows 
the diff erent types of TD in the study population and for the two 
© 2016 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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cohorts. Th e prevalence of the diff erent types of TD was similar 
in Padova and Barcelona, except for Graves’ disease and thyroid 
cancer, which were both more common in the Padova cohort 
(15.7 vs. 5.0%, and 8.6 vs. 1.3%, respectively;  P <0.05). Th e 
diff erence in the thyroid cancer rate between the two cohorts is 
further discussed below. Among the 150 PBC patients with TD, 
34 (22.6%) had been diagnosed with TD before their PBC was 
diagnosed, whereas 116 (77.4%) developed TD during their 
follow-up for PBC.
 No diff erences emerged in the biochemical data between patients 
with and without TD at the time of their PBC being diagnosed 
( Table 3 ). Fatigue was recorded in 86 patients with associated TD 
(57.3%), and in 410 patients without TD (53.2%); the diff erence 
was not statistically signifi cant. A sub-analysis on fatigue was per-
formed in 339 patients in the Barcelona cohort, using the PBC-40, 
a self-administered questionnaire validated for PBC. No diff er-
ences emerged between patients with and without TD in terms of 
the association with fatigue (either as a symptom  per se , or clas-
sifi ed by severity (data not shown). No diff erences were found 
between PBC patients with or without TD regarding liver decom-
 Table 1 .  Clinical characteristics of the study group 
 Characteristic  Padova  Barcelona  Total  P 
 M/F  25/351  42/503  67/854  n.s. 
 Mean age (years)  68±14  70±16  69±15  n.s 
 Mean age at diagnosis (years)  53.2±12.3  51.2±13.1  52.2±12.8  n.s 
 Mean FU (months)  115.2±85.6  135.0±94.9  126.9±91.7  n.s. 
 AMA+  307 (81.7%)  387 (87.6%)  694 (84.9%)  n.s 
 UDCA  352 (93.6%)  409 (92.5%)  761 (93%)  n.s. 
 Smoking  75 (19.9%)  57 (12.9%)  132 (16.1%)  <0.05 
 Alcohol >40 g/die  12 (3.08%)  19 (3.3%)  31 (3.3%)  n.s. 
 Histological stage at diagnosis 
 I  113 (30.1%)  251 (46.1%)  364 (39.5%)  n.s. 
 II  70 (18.6%)  110 (20.2%)  180 (19,5%)  n.s. 
 III  97 (25.8%)  58 (10.6%)  155 (16.8%)  <0.05 
 IV  29 (7.7%)  40 (7.3%)  69 (7.5%)  n.s. 
 Biopsy not performed  67 (17.8%)  86 (15.8%)  153 (16.6%)  n.s. 
 Biochemical data at diagnosis 
 AST (×ULN)  1.67±1.21  1.75±1.3  1.71±1.26  n.s. 
 ALT (×ULN)  1.87±1.45  2.18±1.79  2.05±1.67  n.s. 
 GGT (×ULN)  5.85±5.56  6.47±6.32  6.22±6.02  n.s. 
 ALP (×ULN)  2.47±2.3  2.51±2.17  2.49±2.22  n.s. 
 Bilirubin (mg/dl)  0.74±0.73  1.39±2.68  1.13±2.14  n.s. 
 PTL (×10 9 /l)  241.94±85  238.88±92.02  240.1±89.23  n.s 
 Albumin (mg/dl)  41.42±5.91  41.6±4.85  41.52±5.31  n.s 
 IgG (mg/dl)  1524±577  1602±610  1597±608.23  n.s. 
 IgA (mg/dl)  306.63±130.3  315.6±237.73  315.13±233.3  n.s. 
 IgM (mg/dl)  353±179.89  498.52±591.66  489.16±575.1  n.s. 
 ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Ig, 
immunoglobulins; n.s., not signiﬁ cant; PT, prothrombin time; PTL, platelets; UDCA, ursodeoxycholic acid; ULN, upper normal limit. Values are expressed as 
mean±standard deviation of the total. 
 Table 2 .  Types of thyroid disease (TD) in 150 patients from 
Padova and Barcelona 
 Thyroid disease type  Padova  Barcelona  Total  P 
 Hashimoto’s 
thyroiditis 
 42 (60.0%)  52 (65.0%)  94 (62.7%)  n.s. 
 Graves’ disease  11 (15.7%)  4 (5.0%)  15 (10.0%)  P =0.03 
 Multinodular goiter  10 (14.3%)  12 (15.0%)  22 (14.7%)  n.s. 
 Thyroid cancer  6 8.6%)  1 (1.3%)  7 (4.7%)  P =0.03 
 Others  3 (4.3%)  9 (11.5%)  12 (8.0%)  n.s. 
 n.s., not signiﬁ cant. 
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pensation events or the onset of HCC during the follow-up. Liver 
transplantation was performed in more patients in Barcelona than 
in Padova (9.7 vs. 1.9%,  P <0.001), but the presence of TD did not 
signifi cantly infl uence the indication for liver transplantation. TDs 
were associated with AMA-negative signifi cantly more than with 
AMA-positive PBC patients (22.8 vs. 15.3%,  P =0.04). As expected, 
females had a higher frequency of TD than males (17.1 vs. 5.1%, 
 P =0.001). No signifi cant diff erences in the rate of association with 
TD were found for diff erent histological stages of PBC on presen-
tation. Elderly age (>65 years) was also unassociated with a greater 
frequency of TD in our sample.
 In both cohorts, in Padova and Barcelona, response to UDCA 
was assessed aft er 1 year of therapy according to the following 
criteria: Barcelona ( 16 ), Paris I ( 17 ), Paris II ( 18 ), and Rotterdam 
( 19 ). Th e rate of responders ranged between 67 and 83% ( Table 4 ). 
No signifi cant diff erence in the response rate was found between 
patients with and without associated TD ( Table 4 ).
 In our study population, 147 patients died during the follow-up, 
66 (21.3%) in Padova and 81 (18.2%) in Barcelona ( P =n.s.). Th e 
mean global transplant-free survival rate was 314.4±9.2 months. 
Th e mean transplant-free survival rate of PBC patients with and 
without associated TD was 345.4±21.6 months, and 305.8±10.1 
months, respectively; the diff erence was not signifi cant ( Figure 1 ). 
Using Cox’s regression analysis, adjusted for sex and age, 
survival was not infl uenced by any associated TD or another 
extrahepatic autoimmune condition, SLE or scleroderma/CREST 
or RA, smoking habit or alcohol consumption (>40 g/day), or 
histological stage at diagnosis ( Table 5 ). Survival was also similar 
in patients with and without TD, irrespective of their response to 
UDCA ( P =n.s.)
 Th e overall survival rate was similar in the two cohorts in Padova 
and Barcelona, but when patients without TD were considered 
separately, those in the Padova cohort had a signifi cantly lower 
survival rate than those in Barcelona (248.2±14.3 vs. 320.3±9.3 
months,  P =0.001).
 DISCUSSION
 Th e results of our study confi rm that TD are oft en associated with 
PBC, especially Hashimoto’s thyroiditis, which shares an autoim-
mune etiology with PBC. Th ere were no substantial diff erences in 
the prevalence–incidence of TD among PBC patients at the two 
European centers investigated. More importantly, the presence 
of TD in a PBC patient did not infl uence the rate of hepatic com-
plications or response to UDCA treatment. Indeed, the clinical 
 Table 4 .  Response to UDCA treatment according to the International criteria in patients with and without TD 
 Criteria  UDCA responders with TD  UDCA responders without TD  P  value  OR (95% CI) 
 Barcelona  100 (67%)  497 (64%)  n.s.  1.1162 (0.7198–1.7308) 
 Paris I  105 (69%)  568 (74%)  n.s.  0.8258 (0.5423–1.2576) 
 Paris II  124 (83%)  525 (69%)  n.s.  0.8471 (0.5667–1.2664) 
 Rotterdam  121 (81%)  578 (75%)  n.s.  0.6088 (0.3425–1.0823) 
 n.s., not signiﬁ cant. 
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 Figure 1 .  Kaplan–Meier curves for transplant-free survival in patients with 
and without TD (Breslow generalized Wilcoxon test). 
 Table 3 .  Biochemical data at diagnosis according to the presence 
of thyroid disease (TD) 
 Variable  Patients with 
TD (N. 150) 
 Patients without 
TD (N. 771) 
 P 
 AST (×ULN)  1.71±1.2  1.67±1.24  n.s. 
 ALT (×ULN)  2.1±1.69  1.99±1.6  n.s. 
 GGT (×ULN)  6.04±6.07  5.98±5.8  n.s. 
 ALP (×ULN)  2.32±2.15  2.43±2.22  n.s. 
 Bilirubin (mg/dl)  1.08±2.51  1±1.89  n.s. 
 Albumin (mg/dl)  41.7±4.92  41.6±5.22  n.s. 
 PTL (×10 9 /l)  246±86.11  237±90.11  n.s. 
 IgG (mg/dl)  1629±606.13  1539±581.23  n.s. 
 IgA (mg/dl)  284±155.56  304±255.37  n.s. 
 IgM (mg/dl)  465±306.48  447±635.67  n.s. 
 ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transferase; Ig, immunoglobulins; n.s., 
not signiﬁ cant; PTL, platelets; ULN, upper normal limit. Values are expressed as 
mean±standard deviation of the total. 
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and Barcelona. Th e rate of multinodular goiter in the general 
population varies considerably by geographical area, depending 
mainly on the population’s iodine intake. Both Padova and Barce-
lona are mildly iodine-defi cient areas. Th e Whickham study found 
a 5.9% prevalence of multinodular goiter in the UK ( 22 ).
 We found a signifi cant diff erence in the prevalence of GD 
between the two centers considered (0.7% in Barcelona, 2.9% in 
Padova;  P <0.05). Th ese fi gures are much the same as the prevalence 
of GD in the general population in Spain, and slightly higher than 
the 1.85% for the population at large in Italy ( 21 ). Th e prevalence 
of thyroid cancer was also higher in the PBC cohort than in the 
general population in Padova, confi rming a previously reported 
observation ( 27 ), whereas the prevalence of thyroid cancer in 
the Barcelona cohort was negligible (0.2%). It may be that the 
higher prevalence of thyroid cancer in the Italian cohort refl ects 
the geographical distribution of this neoplasm: Italy has one of 
the highest incidences of thyroid cancer (19.6 per 100,000 person 
years in females), whereas the incidence of this cancer in Spain 
is more than halved (7.8 per 100,000 person years in females) 
( 28 ). Th ese fi gures, drawn from the two countries’ national cancer 
registries, suggest that thyroid cancer might have no correlation 
with PBC.
 Our study showed that an associated TD had no infl uence on 
the natural history of PBC or on patient survival. When our two 
cohorts were considered separately, the presence of TD corre-
lated with a better survival for PBC patients in Padova, but not 
in Barcelona, but the limited information available on the causes 
of death prevented us from investigating this issue adequately. 
It should be noticed that treatment with levothyroxine (used to 
correct clinical hypothyroidism) signifi cantly aff ects a patient’s 
infl ammatory profi le, reducing the pro-infl ammatory cytokines, 
increasing IL-10 levels, and lowering serum IgG concentrations 
( 29,30 ). Levothyroxine therapy might therefore improve coro-
nary microvascular function and thereby prevent cardiovascular 
events ( 31–33 ).
 Th e present study has some obvious limitations. In particular, 
the study design suff ers from some methodological bias: the data-
base was collected on the grounds of the same criteria, and all 
medical histories were checked by consulting patients’ medical 
records concerning thyroid dysfunction, but this procedure was 
not standardized. In addition, the lack of data on causes of death 
should be considered a bias in our survival analysis.
 In conclusion, TDs—and particularly HT—are oft en associated 
with PBC, but do not infl uence the rate of hepatic complications or 
the natural history of the latter disease.
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characteristics and natural history of PBC were much the same 
in the two cohorts, as demonstrated by the absence of signifi cant 
diff erences regarding histological stage at diagnosis (the only 
exception being more patients in stage III in the Italian cohort); 
biochemical data; response to UDCA; the association with other 
extrahepatic autoimmune disorders; the occurrence of clinical 
events; and survival. Th e cohort from Padova included fewer 
patients who received a liver transplant, and there are several rea-
sons for this diff erence, including the age cutoff  for transplanta-
tion (which was strictly 60 years up until 2000), and the number 
of patients dying on the waiting list.
 Th e prevalence of TD is estimated to be higher in the PBC popu-
lation than in the general population both in Italy and in Spain, 
though no specifi c epidemiological data on autoimmune and non-
autoimmune TDs have been published for these two European 
countries to date. As expected, Hashimoto’s thyroiditis (HT) was 
the most common TD in both cohorts (11.2% in Padova and 9.5% 
in Barcelona). Two small studies reported a 3.5% prevalence of HT 
in Spain ( 20 ), and 5% in Italy ( 21 ). It has been estimated that up 
to 5% of the general population have autoimmune TD ( 22,23 ). In 
the Whickham study, conducted in Northern England, the preva-
lence of spontaneous hypothyroidism from Hashimoto’s thyroidi-
tis was 15/1,000 in women (who were diagnosed at a mean 57 years 
of age), and less than 1/1,000 in men ( 22 ). In a 3-year survey of 
1,457,036 inhabitants of a city in Sweden, the incidence of Graves’ 
disease (GD) was 24.5/100,000 a year, and the condition peaked 
among those aged 30–39 years ( 24 ). To date, no published stud-
ies have reported on the prevalence of non-autoimmune thyroid 
conditions in PBC.
 Th e HT rate in our sample was similar to the prevalence pre-
viously reported in other PBC series from diff erent geographical 
areas ( 7,25,26 ), and in other autoimmune disorders as well. Th e 
high prevalence of HT in autoimmune diseases, including PBC, 
may refl ect a common pathogenic mechanism targeting diff erent 
organs. In fact, the probability of a patient with PBC having another 
autoimmune disorders is as high as 61.1% ( 2 ). On the other hand, 
multinodular goiter showed an overall prevalence of 2.4% in the 
PBC population, with no signifi cant diff erence between Padova 
 Table 5 .  Multivariate analysis for survival adjusted for sex and 
age 
  P  value  Exp (B)  95% CI for 
exp (B) 
 Smoking  0.498  1.229  0.677–2.230 
 Alcohol consumption >40 g/day  0.615  0.849  0.449–1.607 
 Histological stage at diagnosis  0.606  1.046  0.883–1.238 
 Extrahepatic autoimmunity  0.840  1.043  0.694–1.568 
 Systemic lupus erithematosus  0.858  1.140  0.271–4.798 
 Scleroderma/CREST  0.975  1.011  0.494–2.072 
 Rheumatoid arthritis  0.379  0.684  0.294–1.594 
 Exp=hazard ratio. 
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Primary biliary cholangitis (PBC) is an autoimmune liver 
disease with a 60% probability of being associated with 
other extrahepatic autoimmune conditions. 
 ✓  Thyroid diseases are often associated with autoimmune 
conditions in women. 
 WHAT IS NEW HERE 
 ✓  Associated thyroid dysfunctions are found in 16.3% of pa-
tients with PBC. Besides Hashimoto’s thyroiditis, clinicians 
should check for Graves’ disease, non-autoimmune thyroid 
diseases and thyroid cancer. 
 ✓  Any associated thyroid diseases do not inﬂ uence the rates 
of hepatic complications or transplant-free survival in PBC 
patients. 
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